Market Spotlight: Acne
Market Spotlight: Acne
$1,318.00
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.e forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 624 million prevalent cases of acne worldwide, and forecasts that number to increase to 683 million prevalent cases by 2026.
- Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with three drugs in the NDA/BLA phase.
- Therapies in mid-to-late-stage development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
- High-impact upcoming events for drugs in the acne space comprise topline Phase II trial results for BTX-1503, topline Phase III trial results for TWIN, and estimated PDUFA dates for FMX101, IDP-123, and CD5789.
- The overall likelihood of approval of a Phase I dermatology-general asset is 25.1%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 8.0 years from Phase I to approval, compared to 7.9 years in the overall dermatology space.
- There have been 21 licensing and asset acquisition deals involving acne drugs during 2014–19. The largest deal was the $650m agreement in 2018 between Almirall and Allergan for the acquisition of a portfolio of five products from Allergan’s Medical Dermatology unit in the US, which comprises of mature and growth brands Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide), and Seysara (sarecycline).
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for acne have been in the late phases of development, with 54% of trials in Phase III–IV, and 46% in Phase I–II.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
- GlaxoSmithKline leads industry sponsors with by far the highest number of clinical trials for acne, followed by Allergan.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Topical therapy
9 Systemic therapy
10 Physical treatments
11 EPIDEMIOLOGY
14 MARKETED DRUGS
19 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 ANT-1207 for Acne (June 25, 2019)
28 VB 1953 for Acne (May 13, 2019)
29 VB 1953 for Acne (May 13, 2019)
31 Winlevi / Breezula for Acne (March 26, 2019)
33 CD5789 for Acne (February 22, 2019)
35 FMX101 for Acne (September 11, 2018)
37 Winlevi / Breezula for Acne (July 10, 2018)
39 Olumacostat Glasaretil for Acne (March 5, 2018)
42 KEY UPCOMING EVENTS
43 KEY REGULATORY EVENTS
43 Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
43 Foamix Submits First Topical Minocycline For Acne
44 PROBABILITY OF SUCCESS
45 LICENSING AND ASSET ACQUISITION DEALS
46 PARENT PATENTS
47 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
53 BIBLIOGRAPHY
53 Prescription information
55 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of acne, 2017–26
19 Figure 2: Overview of pipeline drugs for acne in the US
19 Figure 3: Pipeline drugs for acne, by company
20 Figure 4: Pipeline drugs for acne, by drug type
20 Figure 5: Pipeline drugs for acne, by classification
29 Figure 6: VB 1953 for Acne (May 13, 2019): Phase II – Proof-of-Concept (ex. US)
31 Figure 7: VB 1953 for Acne (May 13, 2019): Phase I – First-In-Human
33 Figure 8: Winlevi / Breezula for Acne (March 26, 2019): Phase III – CB-03-01/27 (Long-Term Extension)
35 Figure 9: CD5789 for Acne (February 22, 2019): Phase III – Perfect 1, Phase III – Perfect 2
37 Figure 10: FMX101 for Acne (September 11, 2018): Phase III – FX2017-22
39 Figure 11: Winlevi / Breezula for Acne (July 10, 2018): Phase III – CB-03-01/25, Phase III – CB-03-01/26
41 Figure 12: Olumacostat Glasaretil for Acne (March 5, 2018): Phase III – CLAREOS-1, Phase III – CLAREOS-2
42 Figure 13: Key upcoming events in acne
44 Figure 14: Probability of success in the acne pipeline
45 Figure 15: Licensing and asset acquisition deals in acne, 2014–19
46 Figure 16: Parent patents in acne
49 Figure 17: Clinical trials in acne
49 Figure 18: Top 10 drugs for clinical trials in acne
50 Figure 19: Top 10 companies for clinical trials in acne
50 Figure 20: Trial locations in acne
51 Figure 21: Acne trials status
52 Figure 22: Acne trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of acne, 2017–26
15 Table 2: Marketed drugs for acne
21 Table 3: Pipeline drugs for acne in the US
27 Table 4: ANT-1207 for Acne (June 25, 2019)
28 Table 5: VB 1953 for Acne (May 13, 2019)
30 Table 6: VB 1953 for Acne (May 13, 2019)
32 Table 7: Winlevi / Breezula for Acne (March 26, 2019)
33 Table 8: CD5789 for Acne (February 22, 2019)
36 Table 9: FMX101 for Acne (September 11, 2018)
37 Table 10: Winlevi / Breezula for Acne (July 10, 2018)
40 Table 11: Olumacostat Glasaretil for Acne (March 5, 2018)
47 Table 12: Historical global sales, by drug ($m), 2014–18
48 Table 13: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the